In a late-stage clinical trial, the single-dose shot lowered the risk of symptomatic illness by 83% and of severe illness by 94%.
RSV cases typically peak between late December and mid-February, but cases last yearAs of late April, the rate of RSV hospitalizations for the current season was around 51 per 100,000 people,GSK’s trial“It’s not like you have to wait to the very last minute because it’s not going to last long enough,” Dormitzer said. “We know from studies we have done that getting a vaccine — for example, in the fall — should cover you through the next RSV season.
So far, commonly reported side effects in the trial include injection site pain, fatigue and muscle pain. Dormitzer said it’s hard to know what to make of the Guillain-Barré case but added, “I would not say it’s a great concern at this point.” The FDA has asked Pfizer to conduct a study on the risk of Guillain-Barré after its vaccine is approved.
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA approves first RSV vaccine to protect older adultsUp to 10,000 deaths and 160,000 hospitalizations a year are caused by RSV.
Read more »
1st RSV vaccine for older adults in US cleared by FDA in historic approvalThe U.S. Food and Drug Administration has approved the first RSV vaccine in the U.S.
Read more »
FDA approves world's first RSV vaccine, a shot for adults ages 60 and upBREAKING: FDA approves the world's first respiratory syncytial virus, or RSV, vaccine made by pharmaceutical giant GSK.
Read more »
FDA approves first vaccine for RSV, a moment six decades in the making | CNNAfter a 60-year scientific quest, the world has its first vaccine to protect against respiratory syncytial virus, or RSV -- and more are on the way.
Read more »
FDA approves GSK RSV vaccineGSK's Arexvy, the first RSV vaccine approved for use in the U.S., gets the green light for older adults.
Read more »